Can a common pill unlock clues to a devastating liver disease?
NCT ID NCT05912387
Summary
This small, early study is testing if a cholesterol-lowering drug called rosuvastatin changes bile acids and gut bacteria in people with primary sclerosing cholangitis (PSC), a rare liver disease with no cure. The goal is to understand the biology of PSC better, which could help guide future drug development. All 15 participants will take the drug for a period, and researchers will measure changes in their bile and microbiome.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.